Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The

Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.

Palisade Bio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $8 price target.

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.